Navigation Links
Presentation at the 14th International Conference on Prenatal Diagnosis and Therapy Highlights Biocept's I.D.Rh(D) Prenatal Diagnostic
Date:6/3/2008

SAN DIEGO, June 3 /PRNewswire/ -- A presentation at the 14th International Conference on Prenatal Diagnosis and Therapy (ISPD) in Vancouver, BC, will highlight Biocept's I.D.Rh(D) Prenatal Diagnostic. I.D.Rh(D) is the first in a series of noninvasive prenatal diagnostic tests that can be performed with a simple maternal blood sample.

The I.D.Rh(D) test diagnoses the Rh(D) status of a fetus in an Rh(D) negative pregnancy, and can be performed as early as ten weeks of gestation. The test isolates fetal DNA circulating in the mother's whole blood, using Biocept's proprietary I.D.(TM) (Isolating Fetal DNA) platform technology (U.S. patents pending). The fetal DNA is analyzed in Biocept's CLIA-accredited clinical laboratory to determine Rh(D) genotype. Similar noninvasive tests have been available routinely in some countries outside the US.

The presentation, to be given by Andrew Brooks, Ph.D., University of Medicine and Dentistry of New Jersey, concludes that isolation of fetal DNA from maternal whole blood for quantitative real-time PCR and Rh(D) genotyping is suitable for routine testing. Testing of multiple markers and controls, which I.D.Rh(D) offers, allows for a high degree of accuracy.

"We are very pleased to see our excellent clinical results validated in an independently reviewed scientific forum such as ISPD," said Gordon F. Janko, president and CEO of Biocept. "The I.D.Rh(D) test, which is now being used commercially, is an important step forward in noninvasive prenatal testing, and provides a higher level of personalized medicine for patients. It is the first of several noninvasive prenatal diagnostics developed in Biocept's laboratories, based on our novel and proprietary technology."

I.D.Rh(D) is the only fetal Rh(D) diagnostic that identifies fetal DNA in maternal blood in all cases in which a diagnosis can be delivered-whether the fetus is male or female, Rh(D) negative or positive.

Until now, the only tests available to definitively diagnose fetal Rh(D) genotype required invasive procedures such as amniocentesis or chorionic villus sampling (CVS), which carry their own risks to the fetus. For this reason, physicians have routinely administered anti-D immune globulin injections, a human blood product, to all Rh(D) negative women at 28-29 weeks of gestation.

About Biocept

Biocept, an emerging biotechnology leader, engineers novel solutions that provide the foundation for a new class of diagnostic assays. Biocept is based in San Diego, California, a major center for academic and industrial life sciences research. Founded in 1997, the company is privately held and draws on a scientific team rich in experience in life science. Its CLIA-accredited clinical laboratory is accredited by the College of American Pathologists and holds licenses in California and other states as required.


'/>"/>
SOURCE Biocept
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Spectral announces presentation of data on improving sepsis patient management with EAA(TM) and Toraymyxin(TM) combination
2. Monogram Announces Presentation of Clinical Data for the HERmark(TM) Breast Cancer Assay at the 44th ASCO Annual Meeting
3. Sequenom to Webcast Analyst and Investor Briefing Presentation on June 3
4. AMT Announces Presentations During the 11th Annual Meeting of the ASGT
5. CV Therapeutics Announces Presentations at the American Diabetes Association 68th Scientific Sessions
6. AVANT Immunotherapeutics Announces Oral Presentation of CDX-110 at ASCO Annual Meeting
7. Presentation of Landmark Clinical Trial Evaluating Endoscopic Treatment for Pre-cancerous Condition of Esophagus
8. Sangamo BioSciences Announces Presentation of Phase 1 Data of ZFP Therapeutic at International Society for Cellular Therapy (ISCT) Meeting
9. Monogram Announces HERmark(TM) Oral Presentation at the 44th ASCO Annual Meeting
10. Bayer and Onyx Announce Nexavar Data Presentations at 44th American Society of Clinical Oncology Annual Meeting
11. Forest Laboratories, Inc. and Laboratorios Almirall, S.A. to Host Webcast to Discuss Aclidinium Bromide Data Presentations at the American Thoracic Society Annual Congress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... -- Global demand for enzymes is forecast to grow ... billion.  This market includes enzymes used in industrial ... animal feed, and other markets) and specialty applications ... beverages will remain the largest market for enzymes, ... containing enzymes in developing regions.  These and other ...
(Date:6/27/2016)... -- Sequenom, Inc. (NASDAQ: SQNM ), a life ... development of innovative products and services, announced today that ... denied its petition to review decisions by ... Patent No. 6,258,540 (",540 Patent") are not patent eligible ... Court,s Mayo Collaborative Services v. Prometheus Laboratories decision.  In ...
(Date:6/27/2016)... Diego, CA (PRWEB) , ... June 27, 2016 , ... ... solutions for clinical trials, announced today the Clinical Reach Virtual Patient Encounter ... their care circle with the physician and clinical trial team. , Using the CONSULT ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... will join the faculty of the University of North Carolina Kenan-Flagler Business ... strategy and entrepreneurship at UNC Kenan-Flagler, with a focus on the school’s international ...
Breaking Biology Technology:
(Date:6/2/2016)... NEW YORK , June 2, 2016   The ... (Weather), is announcing Watson Ads, an industry-first capability in which ... advertising, by being able to ask questions via voice or ... Marketers have long ... with the consumer, that can be personal, relevant and valuable; ...
(Date:5/20/2016)...  VoiceIt is excited to announce its new ... By working together, VoiceIt and VoicePass will offer ... take slightly different approaches to voice biometrics, collaboration ... usability. Both ... "This marketing and technology partnership allows ...
(Date:5/3/2016)...  Neurotechnology, a provider of high-precision biometric identification ... Identification System (ABIS) , a complete system for ... can process multiple complex biometric transactions with high ... face or iris biometrics. It leverages the core ... MegaMatcher Accelerator , which have been used in ...
Breaking Biology News(10 mins):